What is the recommended initiation, titration, and monitoring plan for low‑dose naltrexone in a patient with non‑suicidal self‑injury who has not responded to psychotherapy and has no contraindications such as severe liver disease, opioid use, or hypersensitivity?

Low-Dose Naltrexone for Non-Suicidal Self-Injury: Initiation and Monitoring

There is insufficient high-quality evidence to recommend naltrexone for non-suicidal self-injury (NSSI), as no FDA-approved indication exists for this use and available data consists primarily of small case reports and animal studies. However, given treatment-refractory NSSI with failed psychotherapy and no contraindications, a cautious trial may be considered as an off-label experimental intervention.

Evidence Base and Limitations

The evidence for naltrexone in NSSI is extremely limited. A 2024 review found that studies in animal models suggest low-dose naltrexone (LDN) can prevent habitual self-injury, and a "relatively small number of studies" in humans show that naltrexone 25-50 mg/day may decrease or eliminate self-injurious behaviors 1. However, the authors explicitly state this needs corroboration in larger randomized placebo-controlled trials 1. A 2025 narrative review on NSSI interventions mentions naltrexone only briefly without specific dosing recommendations 2.

This stands in stark contrast to naltrexone's well-established FDA-approved uses for alcohol and opioid dependence, where standard dosing (50 mg daily for alcohol use disorder, 25-50 mg daily for opioid dependence) is supported by placebo-controlled trials 3.

Proposed Initiation Protocol (Off-Label, Experimental)

Given the lack of formal guidelines, the following approach extrapolates from general LDN literature and naltrexone's FDA labeling:

Pre-Treatment Assessment

• Verify opioid-free status: Naltrexone will precipitate severe withdrawal in opioid-dependent patients 3. Confirm no opioid use (including tramadol) for minimum 7-10 days 3
• Baseline liver function tests: Naltrexone carries hepatotoxicity risk at supratherapeutic doses 4. Obtain AST, ALT, bilirubin, alkaline phosphatase
• Document baseline NSSI frequency: Establish objective measurement (e.g., number of self-injury episodes per week, photographic documentation of injuries)
• Screen for contraindications: Active hepatitis, acute liver failure, current opioid therapy, pregnancy

Dosing Strategy

Start with 1.5 mg daily and titrate slowly based on response. The rationale:

• Studies in NSSI used 25-50 mg/day 1, but this is the standard opioid antagonist dose
• LDN literature for chronic pain suggests effective doses are highly individualized, ranging from 0.1-4.5 mg daily 5, 6, 7
• A 2024 observational study demonstrated "hormesis" during dose titration, with maximally effective doses varying widely between patients 5
• Lower doses minimize hepatotoxicity risk (doses >50 mg carry higher hepatic injury risk 3)

Titration schedule:

• Week 1-2: 1.5 mg at bedtime
• Week 3-4: 3 mg at bedtime (if tolerated and insufficient response)
• Week 5-6: 4.5 mg at bedtime (if tolerated and insufficient response)
• Week 7+: Consider increasing to 25 mg if no response at 4.5 mg, given this is the dose range cited in NSSI literature 1

Timing: Administer at bedtime to minimize daytime sedation and capitalize on potential sleep benefits 5.

Monitoring Plan

Short-Term (First 12 Weeks)

Weekly for first 4 weeks, then every 2 weeks:

• NSSI frequency (primary outcome): Number of self-injury episodes, severity, methods used
• Subjective urge to self-injure (0-10 scale)
• Adverse effects: Vivid dreams, insomnia, nausea, dizziness, headache 8
• Mood and energy levels (as LDN may affect these 5)

Laboratory monitoring:

• Liver function tests at 4 weeks, then every 3 months 4
• Discontinue if transaminases rise >3x upper limit of normal

Response Assessment at 12 Weeks

Define treatment success as ≥50% reduction in NSSI frequency. If no meaningful improvement by 12 weeks:

• Consider dose escalation to 25-50 mg daily (the range used in published NSSI cases 1)
• If still no response after 4 additional weeks at higher dose, discontinue
• This mirrors the FDA's recommendation to discontinue naltrexone-bupropion if <5% weight loss at 12 weeks 9

Long-Term Monitoring (If Continuing)

• Monthly NSSI frequency tracking
• Liver function tests every 3-6 months 4
• Reassess need for continuation every 6 months

Critical Caveats and Pitfalls

1. Opioid Blockade: Naltrexone will completely block opioid analgesia 10, 4. If the patient requires surgery or acute pain management:

• Discontinue naltrexone 72 hours before elective procedures (oral naltrexone has ~4-hour half-life but receptor blockade persists longer)
• For emergency surgery, higher opioid doses or non-opioid analgesics will be required
• Document naltrexone use prominently in medical record

2. Precipitated Withdrawal Risk: Even if the patient denies opioid use, occult dependence is possible. Consider naloxone challenge test before initiating if any suspicion 3:

• IV: 0.2 mg naloxone, observe 30 seconds; if no withdrawal, give 0.6 mg and observe 20 minutes
• SC: 0.8 mg naloxone, observe 20 minutes
• If withdrawal signs appear (sweating, tearing, yawning, agitation, mydriasis), do NOT start naltrexone

3. Hepatotoxicity: While generally safe at low doses, monitor liver function vigilantly. Avoid in patients with acute hepatitis or decompensated cirrhosis 11.

4. Lack of Evidence: Explicitly inform the patient this is an experimental, off-label use with minimal supporting data. Document informed consent discussion. Consider this only after evidence-based NSSI treatments (dialectical behavior therapy, emotion regulation training 2) have failed.

5. Pregnancy: Naltrexone is pregnancy category C. Avoid in women of childbearing potential unless using reliable contraception.

Alternative Consideration

If the goal is to trial pharmacotherapy for NSSI, consider selective serotonin reuptake inhibitors (SSRIs) first, as these have more robust evidence for comorbid conditions commonly associated with NSSI (depression, anxiety, borderline personality disorder) and carry less risk than experimental naltrexone use.

The decision to use naltrexone for NSSI should be made collaboratively with the patient, acknowledging the experimental nature, after exhausting evidence-based psychotherapeutic interventions.